Talk:Corcept Therapeutics

Notability of the company
The company's main drug Korlym reached the market in 2012, which focuses on treatment for severe metabolic and psychiatric disorders, and is approved to be prescribed to global patients; this is the first therapy approved by US Food and Drug Administration (FDA) for patients with endogenous Cushing's syndrome. — Preceding unsigned comment added by Whisoseryus (talk • contribs) 12:38, 20 February 2014 (UTC)

Wikipedia Ambassador Program course assignment
This article is the subject of an educational assignment supported by  the Wikipedia Ambassador Program&#32;during the 2014 Spring term. Further details are available on the course page.

The above message was substituted from by PrimeBOT (talk) on 17:21, 2 January 2023 (UTC)